|drug668||Calcium Channel Blockers Wiki||1.00|
|drug223||Angiotensin receptor blocker Wiki||1.00|
|drug3345||Thiazide or Thiazide-like diuretics Wiki||1.00|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a double-blinded, randomized placebo-controlled trial to determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily, for health care workers in the hospital reduces symptomatic and asymptomatic COVID-19 disease during the pandemic. 374 health care workers will be randomized at a 1:1 allocation between the intervention and placebo arms and followed for 90 days. The cumulative incidence of COVID-19 infection in the intervention group will be compared to the cumulative incidence of COVID-19 in the placebo group with relative (risk ratio and 95% CI) and absolute measures (risk difference and 95% CI).
Description: Incidence of symptomatic and asymptomatic COVID-19 infection in health care workersMeasure: Cumulative Incidence of COVID-19 Infection Time: 90 days
Description: Incidence of reported and grade of adverse eventsMeasure: Adverse events incidence Time: 90 days
Description: Duration in days of symptomatic COVID-19 disease in HCW who had diseaseMeasure: Duration of symptomatic COVID-19 disease Time: 90 days
Description: Duration in days of hospitalization attributed to COVID-19 disease in HCW who had diseaseMeasure: Days hospitalized attributed to COVID-19 Time: 90 days
Description: Number of HCW with respiratory failure attributable to COVID-19 disease requiring i) non-invasive ventilation or ii) intubation/mechanical ventilation in HCW who developed diseaseMeasure: Number or respiratory failure attributable to COVID-19 disease Time: 90 days
Description: Cumulative Incidence of Mortality attributed to COVID-19 disease in HCW who developed diseaseMeasure: Mortality Incidence Time: 90 days
Description: Number of days unable to work attributed to COVID-19 in HCW who developed diseaseMeasure: Days of work lost Time: 90 days
Description: Proportion of participants with plasma able to neutralize SARS-CoV-2 virus (plaque reduction neutralization test) in vitro.Measure: Proportion of HCW with plasma able to neutralize SARS-CoV-2 virus Time: 90 days
Description: Number of participants with severity markers of host immune and endothelial activation measured at clinical presentation and their ability to predict severity and outcome.Measure: Number of participants with severity markers of host immune and endothelial activation Time: 90 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports